{
  "pmcid": "2117739",
  "sha256": "471a3cf5da0be342e9c9303d275cb64af1a19aaa2a2854a89e9bf15df08096d2",
  "timestamp_utc": "2025-11-09T23:44:27.645579+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.235196098353995,
    "reading_ease": 24.452229221702908,
    "word_count": 259
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Intrastriatal Carotid Body Autotransplantation in Advanced Parkinson's Disease"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This phase I–II trial involved 13 patients with advanced PD"
      },
      "Participants": {
        "score": 2,
        "evidence": "13 patients with advanced PD, who underwent bilateral stereotactic implantation of CB cell aggregates into the striatum"
      },
      "Intervention": {
        "score": 2,
        "evidence": "bilateral stereotactic implantation of CB cell aggregates into the striatum"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the feasibility, safety, and effects of intrastriatal CB autotransplantation in advanced Parkinson's disease (PD)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in video-blinded Unified Parkinson's Disease Rating Scale III score in the off-medication state."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "This phase I–II trial involved 13 patients with advanced PD"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 12 patients analyzed"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "10 showed clinical improvement in the primary outcome, peaking at 6–12 months post-transplantation (5–74% improvement). Mean improvement at 6 months was 23%."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source]."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}